Methods for the analysis of histone H3 and H4 acetylation in blood

Epigenetics

Volumn 7, Issue 8, 2012, Pages 875-882

  Rigby, Lin ^a,b   Muscat, Andrea ^c   Ashley, David ^c   Algar, Elizabeth ^a,b  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

Author keywords

Histone acetylation; Histone deacetylase inhibitors; LBH589; Paediatrics; Panobinostat

Indexed keywords

HISTONE H3; HISTONE H4; PANOBINOSTAT;

ADOLESCENT; ARTICLE; BLOOD; BLOOD SAMPLING; CASE REPORT; CHILD; CONTROLLED STUDY; FLOW CYTOMETRY; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; NURSE; PHASE 1 CLINICAL TRIAL; PROTEIN ANALYSIS; SCHOOL CHILD; TREATMENT OUTCOME; UMBILICAL CORD BLOOD; WESTERN BLOTTING;

EID: 84864718674     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.20983     Document Type: Article

References (27)

1. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102:3697-702. PMID:15738394; http://dx.doi.org/10.1073/pnas.0500369102.
2. Lindemann RK, Gabrielli B, Johnstone RW. Histonedeacetylase inhibitors for the treatment of cancer. Cell Cycle 2004; 3:779-88. PMID:15153801; http://dx.doi.org/10.4161/cc.3.6.927.
3. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 2001; 7:971-976 PMID:11309348.
4. Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R, et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 2002; 62:6108-6115. PMID:12414635.
5. Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010; 3:5. PMID:20132536;
6. http://dx.doi.org/10.1186/1756-8722-3-5.
7. Maiso P, Carvajal-Vergara X, Ocio EM, López-Pérez R, Mateo G, Gutiérrez N, et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006; 66:5781-5799. PMID:16740717; http://dx.doi.org/10.1158/0008-5472.CAN-05-4186.
8. Kim IA, Kim IH, Kim HJ, Chie EK, Kim JS. HDAC inhibitor-mediated radiosensitization in human carcinoma cells: a general phenomenon? J Radiat Res 2010; 51:257-263. PMID:20505264; http://dx.doi.org/10.1269/jrr.09115.
9. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12:1247-1252. PMID:17962618; http://dx.doi.org/10.1634/theoncologist.12-10-1247.
10. Bertino EM, Otterson GA. Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin Investig Drugs 2011; 20:1151-1158. PMID:21699444; http://dx.doi.org/10.1517/13543784.2011.594437.
11. Ronzoni S, Faretta M, Ballarini M, Pelicci P, Minucci S. New method to detect histone acetylation levels by flow cytometry. Cytometry A 2005; 66:52-61. PMID:15915507; http://dx.doi.org/10.1002/cyto.a.20151.
12. Wiktorowicz JE, Bonner J. Studies on histone acetyltransferase. Partial purification and basic properties. J Biol Chem 1982; 257:12893-900. PMID:7130185.
13. Sureda A, Younes A, Ben-Yehuda D, Ong TC, Kaufman JL, Le Corre C, et al. Final analysis: Phase II study of oral panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous hematopoietic stem cell transplant. 52nd ASH Annual Meeting and Exposition 2010; Abstract 419.
14. Hamberg P, Woo MM, Chen LC, Verweij J, Porro MG, Zhao L, et al. Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer Chemother Pharmacol 2011; 68:805-813. PMID:21706316; http://dx.doi.org/10.1007/s00280-011-1693-x.
15. Dashwood RH, Ho E. Dietary histone deacetylase inhibitors: from cells to mice to man. Semin Cancer Biol 2007; 17:363-369. PMID:17555985; http://dx.doi.org/10.1016/j.semcancer.2007.04.001.
16. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23:3923-3931. PMID:15897550; http://dx.doi.org/10.1200/JCO.2005.14.167.
17. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006; 12:4628-4635. PMID:16899611; http://dx.doi.org/10.1158/1078-0432.CCR-06-0511.
18. Dahl JA, Collas P. Q2ChIP, a quick and quantitative chromatin immunoprecipitation assay, unravels epigenetic dynamics of developmentally regulated genes in human carcinoma cells. Stem Cells 2007; 25:1037-1046. PMID:17272500; http://dx.doi.org/10.1634/stemcells.2006-0430.
19. Johnson DT, Harris RA, French S, Blair PV, You J, Bemis KG, et al. Tissue heterogeneity of the mammalian mitochondrial proteome. Am J Physiol Cell Physiol 2007; 292:689-697. PMID:16928776; http://dx.doi.org/10.1152/ajpcell.00108.2006.
20. Köhler A, Hurt E. Gene regulation by nucleoporins and links to cancer. Mol Cell 2010; 38:6-15. PMID:20385085; http://dx.doi.org/10.1016/j.molcel.2010.01.040.
21. Cremer M, von Hase J, Volm T, Brero A, Kreth G, Walter J, et al. Non-random radial higher-order chromatin arrangements in nuclei of diploid human cells. Chromosome Res 2001; 9:541-567. PMID:11721953; http://dx.doi.org/10.1023/A:1012495201697.
22. Boyle S, Gilchrist S, Bridger JM, Mahy NL, Ellis JA, Bickmore WA. The spatial organization of human chromosomes within the nuclei of normal and emerin- mutant cells. Hum Mol Genet 2001; 10:211-219. PMID:11159939; http://dx.doi.org/10.1093/hmg/10.3.211.
23. Croft JA, Bridger JM, Boyle S, Perry P, Teague P, Bickmore WA. Differences in the localization and morphology of chromosomes in the human nucleus. J Cell Biol 1999; 145:1119-1131. PMID:10366586; http://dx.doi.org/10.1083/jcb.145.6.1119.
24. Tumbar T, Sudlow G, Belmont AS. Large-scale chromatin unfolding and remodeling induced by VP16 acidic activation domain. J Cell Biol 1999; 145:1341-1354. PMID:10385516; http://dx.doi.org/10.1083/jcb.145.7.1341.
25. Shahbazian MD, Grunstein M. Functions of sitespecific histone acetylation and deacetylation. Annu Rev Biochem 2007; 76:75-100. PMID:17362198; http://dx.doi.org/10.1146/annurev.bio-chem.76.052705.162114.
26. Vettese-Dadey M, Grant PA, Hebbes TR, Crane-Robinson C, Allis CD, Workman JL. Acetylation of histone H4 plays a primary role in enhancing transcription factor binding to nucleosomal DNA in vitro. EMBO J 1996; 15:2508-2518. PMID:8665858.
27. Yan C, Boyd DD. Histone H3 acetylation and H3 K4 methylation define distinct chromatin regions permissive for transgene expression. Mol Cell Biol 2006; 26:6357-6371. PMID:16914722; http://dx.doi.org/10.1128/MCB.00311-06.